產(chǎn)品名稱:Bevacizumab ( 貝伐珠單抗 );
產(chǎn)品編號(hào):YR1001;
分子名稱:Bevacizumab;
克隆性:Monoclonal;
產(chǎn)品別稱:12-IgG1, F(ab)-12 IgG1;
關(guān)鍵詞:Anti VEGF, bevacizumab, Anti-Human VEGF Therapeutic Antibody12-IgG1, F(ab)-12 IgG1, Fab-12 IgG1, rhuMAb-VEGF, Anti VEGF, bevacizumab, Bevacizumab, bevacizumab, 216974-75-3, DB00112VEGFA, vascular endothelial growth factor A, vascular endothelial growth factor , VEGF, VEGF A, VPF, vascular permeability factor, VEGF, MVCD1, MGC70609, Anti-Human VEGF Therapeutic Antibody, Bevacizumab, 貝伐珠單抗;
規(guī)格:1mg, 5mg;
濃度:1mg/ml;
抗體亞型:IgG1 Kappa;
宿主:;
CAS號(hào):216974-75-3;
來源:CHO Cells;
純度:≥95% as determined by SDS-PAGE;
緩沖體系:Supplied in PBS, PH7.5;
分子量:149000.00 Da;
產(chǎn)品背景:Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease.;
保存條件:Stored at -20℃ to -80℃.;
運(yùn)輸條件:Shipped on ice packs.;
產(chǎn)品應(yīng)用:FC, IP, ELISA, Neut, FuncS, IF, ICC;
關(guān)鍵字: Anti VEGF, bevacizum;
卡梅德生物科技(天津)有限公司作為國家級(jí)高新技術(shù)企業(yè),專注于為全球科學(xué)家和研究機(jī)構(gòu)提供天然蛋白提取與發(fā)酵、重組蛋白定制表達(dá)服務(wù),單、多克隆抗體開發(fā),噬菌體文庫構(gòu)建與篩選服務(wù);同時(shí),基于我公司成熟的五大核心技術(shù)服務(wù)平臺(tái),成功研發(fā)了眾多用于科學(xué)研究的重組蛋白、抗體、抗體藥物靶點(diǎn)蛋白、工業(yè)酶、診斷原料等相關(guān)試劑。